Body Mass Index Distribution Among Patients with Heart Failure and Reduced Ejection Fraction: Implication for Future Trials

Obesity related heart failure with preserved ejection fraction (HFpEF) has been well described as a distinct phenotype associated with cardiac structural and functional alterations as well as a systemic proinflammatory milieu. Semaglutide, a long-acting glucagon like peptide (GLP)-1 receptor agonist, was recently assessed in patients with HF and an LVEF of ≥45% and obesity (without type 2 diabetes) in the STEP-HFpEF (Semaglutide Treatment Effect in People with Obesity and Heart Failure with preserved Ejection Fraction) trial and was shown to improve symptoms, and exercise capacity, compared with placebo.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Tags: Research Letter Source Type: research